Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announced today that Todd Cooper, President and
CEO, is scheduled to present at the JMP Securities Life Sciences
Conference 2016 on Tuesday, June 21 at 3:00 p.m. ET. The Conference is
being held June 21 and 22, 2016 at The St. Regis New York.
Presbia has developed and is marketing the Presbia Flexivue Microlens™,
a proprietary optical lens implant for treating presbyopia. Mr. Cooper
will discuss Presbia's current international commercial strategy, with a
focus in South Korea, one of the largest ophthalmology markets in the
world. South Korea has one of the highest per capita incidences of
presbyopia, the age-related loss of near-vision, and is also one of the
most penetrated markets for LASIK surgery. The combination of both of
these factors makes South Korea an ideal market for the Company to
launch its innovative solution for presbyopia. Mr. Cooper will also
discuss a peer-to-peer surgeon symposium that is being held in Seoul,
South Korea this month. It will be attended by approximately 20 eminent
South Korean surgeons who have expressed strong interest in the Presbia
Microlens solution for near sightedness.
Mr. Cooper will be available for one-on-one meetings at the Conference.
Information provided and statements contained in this press release that
are not purely historical are forward-looking statements. Such
forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160609005061/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media